코오롱생명과학

102940KOSDAQ

60.8 / 100

Reference Date: 2026-09-08

Financial Score30.0 / 40

News Sentiment19.8 / 25

Momentum4.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 5.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Kolon Life Science operates three business segments: Chemical, SC, and Bio. The Chemical segment, focused on pharmaceutical API production, drives revenue growth due to expanding global pharmaceutical markets and increased outsourcing of raw material production. However, the Bio segment continues to report significant losses.

Number of Employees

454people

Average Salary

60.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.77Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.33Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

6.81Industry Average 8.002.5Point

Below industry avg

Debt Ratio

27.50Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.1% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 79

Positive
코오롱생명과학, 'BIOHK2026' 참가…"글로벌 접점 넓힌다"
코오롱생명과학의 글로벌 바이오테크 전시회 참가로 협업 기회 확대 기대.
Positive
"글로벌 협업 논의"…코오롱생과, 'BIOHK' 참가
코오롱생명과학의 글로벌 바이오테크 전시회 참가로 국제적 네트워크 확장 및 시장 진출 기회 증가 기대.
Positive
코오롱생명과학, 홍콩 바이오 전시회 ‘BIOHK2026’ 출격…공동연...
코오롱생명과학이 국제 바이오 전시회에 참가하여 글로벌 네트워크 확장과 협력 기회를 모색함으로써 긍정적인 시장 반응을 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 14,820Won52-week high 70,80052-week low 13,300

1-month return2.0Point

1m -5.00% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1

Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-31
Neutral[기재정정]반기보고서 (2026.06)2026-08-31
Neutral반기보고서 (2026.06)2026-08-14
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-13